A 2026 mechanistic Alzheimer’s study found that suppressing NDST3 shifted lysosomal pH in APP695Swe neuronal cells from 5.6 back below 5.0, then reduced amyloid-β, MAPT/tau pathology, neuronal injury, and memory deficits in 3xTg-AD mice.1 Research Highlights Lysosome pH moved back down: APP695Swe-overexpressing HT22 cells had lysosomal pH around 5.6, while NDST3 knockdown re-acidified lysosomes to …
A 2026 Cell & Bioscience study found that poly-GR, one of the toxic dipeptide-repeat proteins produced in C9orf72-linked amyotrophic lateral sclerosis (ALS), pushed motor neuron-like cells toward ferroptosis: 4-HNE lipid peroxidation rose at p < 0.0001, labile Fe²+ rose at p < 0.001, and erastin caused more cell death in poly-GR-expressing cells than in control …
A 2026 polysomnography study involving 685 children found that neck-to-height ratio identified moderate/severe pediatric obstructive sleep apnea better than BMI Z-score, waist-to-height ratio, or hip-to-height ratio. The signal was useful but not diagnostic: neck-to-height ratio reached AUC 0.781 overall, which is strong enough for triage but not strong enough to replace a sleep study.1 Research …
A 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural network that combined structural MRI regional features with clinical variables to classify cognitively normal controls, mild cognitive impairment, and Alzheimer’s disease.1 The result is useful, but the clinical-feature ablation dropped accuracy to 68.35%, so the model should be read as multimodal decision-support research, …
A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. The number is large for ALS, but the long-term comparison is historical and modeled rather than randomized placebo follow-up.1 Research Highlights 42.3% reached 5 years from onset: Ludolph et al. …
A 210-person randomized assessor-blinded trial found that adding weekly Hegu-point catgut embedding to gabapentin improved 4-week postherpetic-neuralgia response from 80.00% to 92.38%; compared with gabapentin alone, the add-on arm also ended with lower sleep-problem scores and fewer adverse events.[1] This 2026 trial supports an add-on signal that still needs sham-controlled confirmation because follow-up lasted only …
A 2026 Journal of Neuroinflammation review organized parasite-linked neuropsychiatric risk around 5 gut-immune-brain routes; direct CNS parasitic disease carries the clearest signal, while broader mood and cognition associations usually remain observational and confounded.[1] Research Highlights 5 pathways converge on brain function: the 2026 review connected parasite exposure to peripheral cytokines, gut dysbiosis, intestinal permeability, blood-brain …